Meerut Reporter

Frontotemporal Dementia Pipeline Insight Report | 20+ Companies and 20+ Pipeline Therapies

 Breaking News
  • No posts were found

Frontotemporal Dementia Pipeline Insight Report | 20+ Companies and 20+ Pipeline Therapies

January 17
17:05 2023
Frontotemporal Dementia Pipeline Insight Report | 20+ Companies and 20+ Pipeline Therapies

DelveInsight’s, “Frontotemporal Dementia Pipeline Insight 2023” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Frontotemporal Dementia pipeline landscape. It covers the Frontotemporal Dementia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Frontotemporal Dementia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

“With the increasing numbers of promising treatments entering clinical trials, the Frontotemporal Dementia treatment market is expected to grow significantly in the coming years. There are currently 20+ active players working to develop 20+ pipeline therapies for Frontotemporal Dementia treatment”

 

Key takeaways from the Frontotemporal Dementia Pipeline Insight Report

  • DelveInsight’s Frontotemporal Dementia Pipeline analysis depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Frontotemporal Dementia treatment.
  • Some of the key Frontotemporal Dementia companies developing novel drug candidates to improve the Frontotemporal Dementia treatment landscape include Alector, Prevail Therapeutics, Passage Bio, Inc., Wave Life Sciences Ltd., CAMP4 Therapeutics, Coya Therapeutics, SOLA Biosciences, AcuraStem, Denali Therapeutics, Wave Life Sciences, Neurimmune, Biogen, Asceneuron SA, Libra Therapeutics, Muna Therapeutics, Alkermes, DEEP GENOMICS, Sangamo Therapeutics, LOCANABIO, Arkuda Therapeutics, Yumanity, Autifony Therapeutics, Prothena, Mabylon AG  and others.
  • Key Frontotemporal Dementia pipeline therapies in various stages of development include AL001, TPN-101, PBFT02, PR006, DNL593 (PTV: PRGN), Research programme: CNS therapeutics, NI308, Research Programme: M1 PAM, AS-203, WVE-004, COYA 102, SOL-257, and others.
  • The Frontotemporal Dementia Companies and academics are working to assess challenges and seek opportunities that could influence Frontotemporal Dementia R&D. The Frontotemporal Dementia pipeline therapies under development are focused on novel approaches to treat/improve Frontotemporal Dementia.

 

Recent Developmental Activities in the Frontotemporal Dementia Treatment Landscape

  • In February 2022, Arkuda Therapeutics, announced the completion of a $64 million Series B financing. The financing was co-led by Cormorant Asset Management and Pivotal bioVenture Partners, with participation from Surveyor Capital (a Citadel company), and Eli Lilly and Company, as well as existing investors Atlas Venture, Pfizer Ventures, funds managed by Tekla Capital Management LLC, and Mission BioCapital.
  • In January 2022, The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) announced that they have partnered to support Wave Life Sciences’ FOCUS-C9 Phase 1b/2a clinical trial investigating WVE-004 as a potential treatment for C9orf72-associated frontotemporal degeneration (C9-FTD), as well as amyotrophic lateral sclerosis (C9-ALS).
  • In October 2021, Libra Therapeutics, Inc. announced the appointment of Philip Lambert, Ph.D., as the company’s first CSO. With more than 25 years of drug discovery and development expertise in the areas of neuroscience, metabolic, inflammatory, and orphan diseases and a neuroscientist by training, Dr. Lambert will lead Libra’s development of novel drug candidates focused on restoring the cellular balance lost in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
  • In July 2021, GlaxoSmithKline plc and Alector entered into a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels.
  • In July 2021, Muna Therapeutics announced the successful closing of a USD 73 million (EUR 60 million) Series A financing round. The investor syndicate was co-led by Novo Holdings, Sofinnova Partners, Droia Ventures, and LSP Dementia Fund, with Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures, and VIB joining the round. Muna discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia, and Parkinson’s.

 

Discover the recent breakthroughs happening Frontotemporal Dementia pipeline landscape @ Frontotemporal Dementia Pipeline Outlook

 

Frontotemporal Dementia Overview

Frontotemporal dementia is an uncommon type of dementia that causes problems with behaviour and language. Dementia is the name for problems with mental abilities caused by gradual changes and damage in the brain. Frontotemporal dementia affects the front and sides of the brain (the frontal and temporal lobes).Dementia mostly affects people over 65, but frontotemporal dementia tends to start at a younger age. Most cases are diagnosed in people aged 45-65, although it can also affect younger or older people. Like other types of dementia, frontotemporal dementia tends to develop slowly and get gradually worse over several years. Signs of frontotemporal dementia can include: personality and behaviour changes – acting inappropriately or impulsively, appearing selfish or unsympathetic, neglecting personal hygiene, overeating, or loss of motivation, language problems – speaking slowly, struggling to make the right sounds when saying a word, getting words in the wrong order, or using words incorrectly, problems with mental abilities – getting distracted easily, struggling with planning and organisation.

 

Frontotemporal Dementia Emerging Drugs 

 

PR 006 : Prevail Therapeutics

PR006 is being developed as a potentially disease-modifying, single-dose gene therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN). PR006 is designed to slow or stop disease progression in FTD-GRN patients by increasing progranulin levels via delivery of a healthy GRN gene into the central nervous system (CNS). PR006 is administered by injection into the cisterna magna, using the well-studied viral vector AAV9.The U.S. FDA has granted Orphan Drug designation for the treatment of FTD and Fast Track designation for the treatment of FTD-GRN. The European Commission has granted orphan designation for PR006 for the treatment of FTD.PR006 is currently being studied in our PROCLAIM trial, a Phase 1/2 clinical trial of PR006 for the treatment of patients with FTD-GRN. 

Latozinemab : Alector

AL001 modulates progranulin (PGRN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. We are initially developing AL001 for frontotemporal dementia (FTD) with progranulin mutation (FTD-GRN). The global INFRONT-3 Phase 3 clinical trial is currently enrolling both at-risk and symptomatic participants with FTD-GRN.AL001 is being developed in collaboration with GSK. 

PBFT 02 : Passage Bio

Passage Bio, gene therapy product candidate, PBFT02, an AAV1 viral vector to deliver a modified DNA encoding the granulin gene (GRN) to a patient’s cells. The vector will be delivered directly to the cerebrospinal fluid by a single injection to the cisterna magna (ICM injection). The goal of this vector and delivery approach is to provide higher-than-normal levels of the progranulin protein (PGRN) to the CNS to overcome the progranulin deficiency in GRN gene mutation carriers. Currently the product is in Phase I/II for the treatment of Frontotemporal Dementia. 

WVE 004 : WaVe life Sciences

WVE-004 is an investigational variant-selective silencing candidate designed to selectively target the transcript variants containing a hexanucleotide repeat expansion (G4C2) in the C9orf72 gene, while sparing the healthy C9orf72 protein. G4C2 expansions are one of the most common genetic causes of the sporadic and inherited forms of ALS and FTD. 

EXO 050 : Coya Therapeutics

EXO 050, is the lead drug candidate of Coya Therapeutics for the treatment of FTD.Currently, the drug is in Pre-Clinical stage of development for the treatment of FTD.  

 

To find out more facts about the Frontotemporal Dementia Emerging Drugs, visit for more information @ Frontotemporal Dementia Ongoing Clinical Trials

 

Frontotemporal Dementia Therapeutic Assessment

There are approx. 20+ key companies which are developing the therapies for Frontotemporal Dementia. The Frontotemporal Dementia Companies which have their Frontotemporal Dementia drug candidates in the most advanced stage, i.e. phase III include, Alector.

 

Frontotemporal Dementia Therapeutics Segmentation

The Frontotemporal Dementia Pipeline report proffers an integral view of the Frontotemporal Dementia emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

 

Learn more about the novel Frontotemporal Dementia emerging therapies @ Frontotemporal Dementia Treatment Landscape

 

Scope of the Frontotemporal Dementia Pipeline Report

  • Coverage- Global
  • Frontotemporal Dementia Companies: Alector, Prevail Therapeutics, Passage Bio, Inc., Wave Life Sciences Ltd., CAMP4, Therapeutics, Coya Therapeutics, SOLA Biosciences, AcuraStem, Denali Therapeutics, Wave Life Sciences, Neurimmune, Biogen, Asceneuron SA, Libra Therapeutics, Muna Therapeutics, Alkermes, DEEP GENOMICS, Sangamo Therapeutics, LOCANABIO, Arkuda Therapeutics, Yumanity, Autifony Therapeutics, Prothena, Mabylon AG, and others.
  • Frontotemporal Dementia Pipeline Therapies: AL001, TPN-101, PBFT02, PR006, DNL593(PTV: PRGN), Research programme: CNS therapeutics, NI308, Research Programme: M1 PAM, AS-203, WVE-004, COYA 102,  SOL-257, and others.
  • Frontotemporal Dementia Segmentation: Phases, Product Type, Mechanism of Action, Route of Administration, Molecule Type

 

Table of Content

  1. Introduction
  2. Frontotemporal Dementia Executive Summary
  3. Frontotemporal Dementia: Overview
  4. Frontotemporal Dementia Pipeline Therapeutics
  5. Frontotemporal Dementia Therapeutic Assessment
  6. Frontotemporal Dementia– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. Drug name: Company name
  9. Drug profiles in the detailed report…..
  10. Last Stage Products (Phase III)
  11. Latozinemab : Alector
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (PhaseI/ II)
  14. PR 006 : Prevail Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. EXO 050 : Coya Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Frontotemporal Dementia Key Companies
  21. Frontotemporal Dementia Key Products
  22. Frontotemporal Dementia – Unmet Needs
  23. Frontotemporal Dementia – Market Drivers and Barriers
  24. Frontotemporal Dementia – Future Perspectives and Conclusion
  25. Frontotemporal Dementia Analyst Views
  26. Frontotemporal Dementia Key Companies
  27. Appendix

 

For further information on the Frontotemporal Dementia current pipeline therapeutics, reach out to Frontotemporal Dementia Key Companies and Therapies

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/brucellosis-market